-
Something wrong with this record ?
The New Possibilities in Early Diagnosis of Preeclampsia by Soluble fms-Like Tyrosine Kinase-1 and Placental Growth Factor in 16-20 Weeks Gestation
M. Benovská, A. Opluštilová, J. Pinkavová, Z. Hodická, Z. Cermáková,
Language English Country England, Great Britain
Document type Journal Article
NLK
ProQuest Central
from 2011-05-01 to 1 year ago
Open Access Digital Library
from 1970-01-01
Nursing & Allied Health Database (ProQuest)
from 2011-05-01 to 1 year ago
Health & Medicine (ProQuest)
from 2011-05-01 to 1 year ago
Public Health Database (ProQuest)
from 2011-05-01 to 1 year ago
PubMed
29267975
DOI
10.1093/labmed/lmx076
Knihovny.cz E-resources
- MeSH
- Adult MeSH
- Humans MeSH
- Young Adult MeSH
- Placenta Growth Factor blood MeSH
- Pre-Eclampsia blood diagnosis MeSH
- Vascular Endothelial Growth Factor Receptor-1 blood MeSH
- Retrospective Studies MeSH
- Sensitivity and Specificity MeSH
- Pregnancy MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Young Adult MeSH
- Pregnancy MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
Background: Soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) are used in diagnosing preeclampsia (PE), but their potential in early prediction in pregnant women at 16 to 20 weeks gestation (WG) has remained unexplored. Methods: We retrospectively measured serum levels of sFlt-1 and PlGF in 120 pregnant women at 16 to 20 WG. Among these women, 16 had early-onset PE and 23 had late-onset PE. Results: Compared with normal pregnancy values, in the serum of women in whom PE later developed, sFlt-1 values increased (P <.001), values of PlGF decreased (P = .001), and the sFlt-1/PlGF ratio increased (P <.001) as early as 16 to 20 WG. Receiver operating characteristic (ROC) curve analysis for the sFlt-1/PlGF ratio at 16 to 20 WG showed an area under the curve (AUC) value of 0.863 (95% confidence interval [CI], 0.788-0.918), P <.001, sensitivity of 74.4%, and specificity of 86.6% for PE in general; and AUC of 0.970 (95% CI, 0.913-0.994), P <.001, sensitivity of 100%, and specificity of 81.5% for early-onset PE only. Also, we determined the 5th and 95th percentiles for sFlt-1, PlGF, and sFlt-1/PlGF ratio values of healthy pregnant women. Conclusion: sFlt-1 and PlGF and, in particular, the sFlt-1/PlGF ratio can detect PE as early as 16 to 20 WG-as long as 10 to 15 weeks before PE onset.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc18024416
- 003
- CZ-PrNML
- 005
- 20180717091610.0
- 007
- ta
- 008
- 180709s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1093/labmed/lmx076 $2 doi
- 035 __
- $a (PubMed)29267975
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Benovská, Miroslava $u Department of Clinical Biochemistry, The University Hospital Brno, Czech Republic. Department of Laboratory Methods, Faculty of Medicine, Masaryk University, Czech Republic.
- 245 14
- $a The New Possibilities in Early Diagnosis of Preeclampsia by Soluble fms-Like Tyrosine Kinase-1 and Placental Growth Factor in 16-20 Weeks Gestation / $c M. Benovská, A. Opluštilová, J. Pinkavová, Z. Hodická, Z. Cermáková,
- 520 9_
- $a Background: Soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) are used in diagnosing preeclampsia (PE), but their potential in early prediction in pregnant women at 16 to 20 weeks gestation (WG) has remained unexplored. Methods: We retrospectively measured serum levels of sFlt-1 and PlGF in 120 pregnant women at 16 to 20 WG. Among these women, 16 had early-onset PE and 23 had late-onset PE. Results: Compared with normal pregnancy values, in the serum of women in whom PE later developed, sFlt-1 values increased (P <.001), values of PlGF decreased (P = .001), and the sFlt-1/PlGF ratio increased (P <.001) as early as 16 to 20 WG. Receiver operating characteristic (ROC) curve analysis for the sFlt-1/PlGF ratio at 16 to 20 WG showed an area under the curve (AUC) value of 0.863 (95% confidence interval [CI], 0.788-0.918), P <.001, sensitivity of 74.4%, and specificity of 86.6% for PE in general; and AUC of 0.970 (95% CI, 0.913-0.994), P <.001, sensitivity of 100%, and specificity of 81.5% for early-onset PE only. Also, we determined the 5th and 95th percentiles for sFlt-1, PlGF, and sFlt-1/PlGF ratio values of healthy pregnant women. Conclusion: sFlt-1 and PlGF and, in particular, the sFlt-1/PlGF ratio can detect PE as early as 16 to 20 WG-as long as 10 to 15 weeks before PE onset.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a placentární růstový faktor $x krev $7 D000072483
- 650 _2
- $a preeklampsie $x krev $x diagnóza $7 D011225
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a retrospektivní studie $7 D012189
- 650 _2
- $a senzitivita a specificita $7 D012680
- 650 _2
- $a receptor 1 pro vaskulární endoteliální růstový faktor $x krev $7 D040281
- 650 _2
- $a mladý dospělý $7 D055815
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Opluštilová, Aneta $u Department of Clinical Biochemistry, The University Hospital Brno, Czech Republic.
- 700 1_
- $a Pinkavová, Jana $u Department of Clinical Biochemistry, The University Hospital Brno, Czech Republic.
- 700 1_
- $a Hodická, Zuzana $u Department of Gynecology and Obstetrics, The University Hospital Brno and Faculty of Medicine, Masaryk University, Czech Republic.
- 700 1_
- $a Cermáková, Zdenka $u Department of Clinical Biochemistry, The University Hospital Brno, Czech Republic. Department of Laboratory Methods, Faculty of Medicine, Masaryk University, Czech Republic.
- 773 0_
- $w MED00003113 $t Laboratory medicine $x 1943-7730 $g Roč. 49, č. 2 (2018), s. 112-117
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/29267975 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20180709 $b ABA008
- 991 __
- $a 20180717091909 $b ABA008
- 999 __
- $a ok $b bmc $g 1316547 $s 1021337
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 49 $c 2 $d 112-117 $i 1943-7730 $m Laboratory medicine $n Lab Med $x MED00003113
- LZP __
- $a Pubmed-20180709